Global Chronic Heart Failure Market Size to Exceed USD 18.44 Billion by 2035 | CAGR of 9.32%

Global Chronic Heart Failure Market Size to Exceed USD 18.44 Billion by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The Global Chronic Heart Failure Market Size is expected to Grow from USD 6.92 Billion in 2024 to USD 18.44 Billion by 2035, at a CAGR of 9.32% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Chronic Heart Failure Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Diuretics, Aldosterone Antagonists, and Vasodilators), By Route of Administration (Oral, Intravenous, and Subcutaneous), By Therapeutic Intervention (Medication Therapy Management, Device-Based Therapy (e.g., ICDs, CRT), and Cardiac Rehabilitation Programs), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." 

Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/chronic-heart-failure-market                  

The chronic heart failure (CHF) market pertains to the worldwide healthcare sector dedicated to diagnosing, treating, and managing individuals with chronic heart failure, including medications, medical instruments, diagnostic tools, and supportive care services. Congestive heart failure, also known as chronic heart failure (CHF), is a progressive condition where the heart is unable to pump sufficient blood to meet the body's needs. Some common signs of the illness include irregular heartbeat, fatigue, shortness of breath, chest discomfort, nausea, swelling in the legs, ankles, and feet, coughing, and various other symptoms. The chronic heart failure (CHF) market is expanding due to the increasing global population, growing prevalence of cardiovascular diseases, and heightened awareness of healthcare. Moreover, advancements in treatment options, including new drugs, medical innovations, and personalised therapies, are fueling market growth. Furthermore, enhanced disease management and tailored strategies are contributing to better case outcomes. The high treatment costs, prevalence of generic drugs, and complex management of comorbidities hinder the accessibility and innovation of this market expansion.

The angiotensin-converting enzyme (ACE) inhibitors segment accounted for the largest share in 2024 and is projected to grow at a substantial CAGR over the forecast period.       

Based on the drug class, the chronic heart failure market is divided into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, diuretics, aldosterone antagonists, and vasodilators. Among these, the angiotensin-converting enzyme (ACE) inhibitors segment accounted for the largest share in 2024 and is projected to grow at a substantial CAGR over the forecast period. The main drug for CHF is the first line of therapy. It encompasses drugs like Prinivil (lisinopril), Vasotec, Zestril, Qbrelis, captopril, and Epaned (enalapril)

The oral segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.     

Based on the route of administration, the chronic heart failure market is segmented into oral, intravenous, and subcutaneous. Among these, the oral segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The increasing population of older adults, who are primarily impacted by CHF, often prefer tablets due to their ease of use, contributing to segmental growth.

The device-based therapy (e.g., ICDs, CRT) segment accounted for a significant share in 2024 and is anticipated to grow at a rapid pace over the forecast period.     

Based on the therapeutic intervention, the chronic heart failure market is divided into medication therapy management, device-based therapy (e.g., ICDs, CRT), and cardiac rehabilitation programs. Among these, the device-based therapy (e.g., ICDs, CRT) segment accounted for a significant share in 2024 and is anticipated to grow at a rapid pace over the forecast period. The segment's growth is being driven by the use of pharmaceuticals and medical device research and development. Moreover, as it maintains heart rhythm without inducing discomfort, it is gaining popularity among patients and surgeons.

Asia Pacific is anticipated to hold the majority share of the global chronic heart failure market during the forecast period.       

Asia Pacific is anticipated to hold the majority share of the global chronic heart failure market during the forecast period. The ageing population vulnerable to CHF is increasing due to the region's larger population and longer life expectancy. India's large population, increasing disposable incomes, and growing healthcare expenditures all played a role in the country's substantial market share for medications for congestive heart failure.

North America is anticipated to grow at the fastest pace in the global chronic heart failure market during the forecast period. The significant disease burden, increasing patient awareness, and escalating healthcare expenses are responsible. In 2023, the United States dominated the North American market for congestive heart failure drugs, attributed to its large elderly demographic, inactive lifestyle, and increasing obesity levels.

Major vendors in the global chronic heart failure market are Abbott, Abiomed, Biovail Corporation, Boston Scientific Corporation, Bristol-Myers Squibb Company, GlaxoSmithKline plc, HeartWare, Johnson & Johnson, Medtronic, Merck, New Haven Pharmaceuticals Inc., Novartis International AG, Pfizer, Stanley Pharmaceuticals, and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In August 2025, Merck published updated Phase 3 findings for VERQUVO (vericiguat) in chronic heart failure with reduced ejection fraction (HFrEF). The VICTOR trial failed to achieve its main objective, yet combined analyses with the previous VICTORIA trial indicated a significant advantage in lowering cardiovascular death or heart failure hospitalisations.

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors and Consulting has segmented the chronic heart failure market based on the below-mentioned segments:

Global Chronic Heart Failure Market, By Drug Class

• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Beta-Blockers
• Diuretics
• Aldosterone Antagonists
• Vasodilators

Global Chronic Heart Failure Market, By Route of Administration

• Oral
• Intravenous
• Subcutaneous

Global Chronic Heart Failure Market, By Therapeutic Intervention

• Medication Therapy Management
• Device-Based Therapy (e.g., ICDs, CRT)
• Cardiac Rehabilitation Programs

Global Chronic Heart Failure Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa